Biosense technology enables 3D electromechanical mapping of the left ventricle without fluoroscopy to guide catheter-based diagnostics and therapeutics.
May reduce fluoroscopy exposure in LV mapping; leaves open prospective validation of safety and outcomes.
Biosense is a new technology for left ventricular endocardial mapping and catheter-based intramyocardial therapeutics. The system reconstructs electromechanical maps of the left ventricle without using x-ray fluoroscopy. The 3-dimensional electromechanical maps generated by the system are utilized to precisely identify viable target zones based on integration of endocardial electrical and mechanical signals for online diagnosis of myocardial viability in the catheterization laboratory. It may be used for guidance of radiofrequency ablation and may potentially be used to apply intramyocardial therapy by its integration with a laser fiber for transmyocardial laser revascularization procedures.
No takes yet. Share an insight, caveat, or question.
Bhargava et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: